程序性细胞死亡因子4在肿瘤中的研究进展

摘要/Abstract

摘要：程序性细胞死亡因子4（PDCD4）为新近发现的抑癌基因，其表达受PDCD4基因甲基化、多种微小RNA的抑制。PDCD4编码的蛋白质可增强多种肿瘤细胞对抗肿瘤药物的敏感性，抑制肿瘤的发生发展和侵袭转移进程，在多种肿瘤中发挥重要作用，有望成为临床上判断肿瘤预后的重要指标。

赵莉莉，张梅，朱耀东. 程序性细胞死亡因子4在肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2017, 44(7): 512-515.

Zhao Lili, Zhang Mei, Zhu Yaodong. Research progress of programmed cell death 4 in tumors[J]. Journal of International Oncology, 2017, 44(7): 512-515.

［1］ Soejima H, Miyoshi O, Yoshinaga H, et al. Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization［J］. Cytogenet Cell Genet, 1999, 87(12): 113-114. DOI: 15408. ［2］ Waters LC, Strong SL, Ferlemann E, et al. Structure of the tandem MA3 region of Pdcd4 protein and characterization of its interactions with eIF4A and eIF4G: molecular mechanisms of a tumor suppressor［J］. J Biol Chem, 2011, 286(19): 1727017280. DOI: 10.1074/jbc.M110.166157. ［3］ Fan H, Zhao Z, Quan Y, et al. DNA methyltransferase 1 knockdown induces silenced CDH1 gene reexpression by demethylation of methylated CpG in hepatocellular carcinoma cell line SMMC7721［J］. Eur J Gastroenterol Hepatol, 2007, 19(11): 952961. DOI: 10.1097/MEG.0b013e3282c3a89e. ［4］ Gao F, Wang X, Zhu F, et al. PDCD4 gene silencing in gliomas is associated with 5′CpG island methylation and unfavourable prognosis［J］. J Cell Mol Med, 2009, 13(10): 4257-4267. DOI: 10.1111/j.15824934.2008.00497.x. ［5］孙娜. DNMT1和PDCD4在胃癌及癌前病变中的表达及其临床意义［D］. 济南: 山东大学, 2012. ［6］李日恒, 杨瑞红, 宋艳敏, 等. 结直肠癌组织中PAQR3、PDCD4基因甲基化水平与结直肠癌的关系［J］. 中国老年学杂志, 2015, 35(13): 3633-3635. DOI: 10.3969/j.issn.1005-9202.2015.13.069. ［7］ Sekar D, Krishnan R, Thirugnanasambantham K, et al. Significance of microRNA 21 in gastric cancer［J］. Clin Res Hepatol Gastroenterol, 2016, 40(5): 538-545. DOI: 10.1016/j.clinre.2016.02.010. ［8］ Cao Z, Yoon JH, Nam SW, et al. PDCD4 expression inversely correlated with miR21 levels in gastric cancers［J］. J Cancer Res Clin Oncol, 2012, 138(4): 611-619. DOI: 10.1007/s00432-011-1140-8. ［9］ Wen SW, Zhang YF, Li Y, et al. Characterization and effects of miR21 expression in esophageal cancer［J］. Genet Mol Res, 2015, 14(3): 8810-8818. DOI: 10.4238/2015.August.3.4. ［10］ Peacock O, Lee AC, Cameron F, et al. Inflammation and miR21 pathways functionally interact to downregulate PDCD4 in colorectal cancer［J］. PLoS One, 2014, 9(10): e110267. DOI: 10.1371/journal.pone.0110267. ［11］ Frampton AE, Castellano L, Colombo T, et al. Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progression［J］. Lancet (London, England), 2015, 385(Suppl 1): S37. DOI: 10.1016/S0140-6736(15)60352-X. ［12］ Frampton AE, Castellano L, Colombo T, et al. MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression［J］. Gastroenterology, 2014, 146(1): 268277, e18. DOI: 10.1053/j.gastro.2013.10.010. ［13］ Yang M, Liu R, Li X, et al. miRNA183 suppresses apoptosis and promotes proliferation in esophageal cancer by targeting PDCD4［J］. Mol Cells, 2014, 37(12): 873-880. DOI: 10.14348/molcells.2014.0147. ［14］ Ren LH, Chen WX, Li S, et al. MicroRNA-183 promotes proliferation and invasion in oesophageal squamous cell carcinoma by targeting programmed cell death 4［J］. Br J Cancer, 2014, 111(10): 2003-2013. DOI: 10.1038/bjc.2014.485. ［15］ Gu W, Gao T, Shen J, et al. MicroRNA-183 inhibits apoptosis and promotes proliferation and invasion of gastric cancer cells by targeting PDCD4［J］. Int J Clin Exp Med, 2014, 7(9): 2519-2529. ［16］ Lu YY, Zheng JY, Liu J, et al. miR-183 induces cell proliferation, migration, and invasion by regulating PDCD4 expression in the SW1990 pancreatic cancer cell line［J］. Biomed Pharmacother, 2015, 70: 151-157. DOI: 10.1016/j.biopha.2015.01.016. ［17］ Lei Y, Hu X, Li B, et al. miR150 modulates cisplatin chemosensitivity and invasiveness of muscleinvasive bladder cancer cells via targeting PDCD4 in vitro［J］. Med Sci Monit, 2014, 20: 1850-1857. DOI: 10.12659/MSM.891340. ［18］ Ning FL, Wang F, Li ML, et al. MicroRNA182 modulates chemosensitivity of human nonsmall cell lung cancer to cisplatin by targeting PDCD4［J］. Diagn Pathol, 2014, 9: 143. DOI: 10.1186/1746-1596-9-143. ［19］ Li H, Xu H, Shen H, et al. microRNA106a modulates cisplatin sensitivity by targeting PDCD4 in human ovarian cancer cells［J］. Oncol Lett, 2014, 7(1): 183188. DOI: 10.3892/ol.2013.1644. ［20］ Wei X, Wang W, Wang L, et al. MicroRNA21 induces 5fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4［J］. Cancer Med, 2016, 5(4): 693-702. DOI: 10.1002/cam4.626. ［21］ Xu H, Dephoure N, Sun H, et al. Proteomic profiling of paclitaxel treated cells identifies a novel mechanism of drug resistance mediated by PDCD4［J］. J Proteome Res, 2015, 14(6): 24802491. DOI: 10.1021/acs.jproteome.5b00004. ［22］王汉卿, 孙震晓. 抑癌基因Pdcd4的表达对羟基喜树碱细胞毒活性的影响［J］. 世界华人消化杂志, 2009, 17(7): 647-651. DOI: 10.3969/j.issn.1009-3079.2009.07.003. ［23］ Fassan M, Cagol M, Pennelli G, et al. Programmed cell death 4 protein in esophageal cancer［J］. Oncol Rep, 2010, 24(1): 135-139. ［24］ Fassan M, Pizzi M, Battaglia G, et al. Programmed cell death 4 (PDCD4) expression during multistep Barrett′s carcinogenesis［J］. J Clin Pathol, 2010, 63(8): 692-696. DOI: 10.1136/jcp.2010.078253. ［25］ Yu H, Zeng J, Liang X, et al. Helicobacter pylori promotes epithelialmesenchymal transition in gastric cancer by downregulating programmed cell death protein 4 (PDCD4)［J］. PLoS One, 2014, 9(8): e105306. DOI: 10.1371/journal.pone.0105306. ［26］ Liang H, Wang F, Chu D, et al. miR93 functions as an oncomiR for the downregulation of PDCD4 in gastric carcinoma［J］. Sci Rep, 2016, 6: 23772. DOI: 10.1038/srep23772. ［27］ Wang LY, Zhao MS, Guo C, et al. PDCD4 deficiency aggravated colitis and colitisassociated colorectal cancer via promoting IL6/STAT3 pathway in mice［J］. Inflamm Bowel Dis, 2016, 22(5): 11071118. DOI: 10.1097/MIB.0000000000000729. ［28］ Liu Y, Guo Y, Liang H, et al. miR181b functions as an oncomiR in colorectal cancer by targeting PDCD4［J］. Protein Cell, 2016, 7(10): 722-734. DOI: 10.1007/s13238-016-0313-2.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

程序性细胞死亡因子4在肿瘤中的研究进展

Research progress of programmed cell death 4 in tumors

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价